Acorda Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 7.48
Dividend & YieldN/A$ (N/A)
Beta 1.66
Market capitalization 15.03M
Operating cash flow -26.75M
ESG Scores unknown

Company description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio1.55
Working Capital-2.16
Return On Equity-0.69
Debt To Equity1.18
Fixed Asset Ratio0.84
Fixed Interest Cover-2.37

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -3.49M -60.56M -8.97M 1.11M
Total Cashflows From Investing Activities -176.87M -505k 59.36M 73.78M
Net Borrowings -657k -55.81M -597k -69.66M
Total Cash From Financing Activities 12.8M -60.55M -1.67M -69.66M
Change To Operating Activities -15.32M 14.02M -1.42M 12.78M
Issuance Of Stock 15.2M 24k
Net Income 33.68M -272.97M -99.59M -103.95M
Change In Cash -13.69M -189.16M -2.3M -37.67M
Effect Of Exchange Rate -412k 62k 1.02M -447k
Total Cash From Operating Activities 150.79M -128.17M -61.01M -41.35M
Depreciation 10.78M 33.97M 40.9M 33.65M
Change To Account Receivables 57.97M 1.35M 1.89M 3.19M
Other Cashflows From Financing Activities -4.67M -4.67M -1.07M
Change To Netincome 42.2M 135.91M -7.18M -12.56M
Capital Expenditures -33.33M -90.43M -4.39M -165k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 105.18M
Income Before Tax 20.42M -274.25M -107.67M -109.07M
Net Income 33.68M -272.97M -99.59M -103.95M
Selling General Administrative 172.15M 189.85M 152.58M 119M
Gross Profit 373.79M 98.88M 96.78M 78.46M
Ebit 94.79M -116.61M -86.55M -71.3M
Operating Income 94.79M -116.61M -86.55M -71.3M
Interest Expense -21.6M -21.87M -30.57M -30.04M
Income Tax Expense -13.26M -1.28M -8.07M -5.12M
Total Revenue 471.43M 192.41M 152.97M 129.07M
Cost Of Revenue 97.64M 93.53M 56.18M 50.61M
Total Other Income ExpenseNet -74.36M -157.64M -21.11M -37.77M
Net Income From Continuing Ops 33.68M -272.97M -99.59M -103.95M
Net Income Applicable To Common Shares 33.68M -272.97M -99.59M -103.95M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 687.68M 488.9M 394.73M 304.33M
Total Stockholder Equity 611.98M 310.82M 237.96M 151.14M
Other Current Liabilities 13.9M 12.7M 10.36M 8.24M
Total Assets 1.3B 799.72M 632.68M 455.47M
Common Stock 48k 8k 9k 13k
Other Current Assets 10.73M 16.4M 86.29M 14.4M
Retained Earnings -393.84M -666.81M -766.4M -870.36M
Treasury Stock 673k -1.81M -3.44M -1.66M
Cash 293.56M 62.09M 71.37M 45.63M
Total Current Liabilities 140.26M 86.39M 137.25M 54.02M
Other Stockholder Equity 2.81M -1.17M -2.8M -1.02M
Property, Plant, and Equipment 60.52M 165.98M 25.74M 11.13M
Total Current Assets 528.11M 201.11M 221.34M 102.16M
Net Tangible Assets -98.65M -91.51M -129.03M -184.84M
Net Receivables 23.43M 22.08M 20.19M 17M
Accounts Payable 48.86M 26.26M 12.15M 10.85M


Insider Transactions

Here are the insider transactions of stock shares related to Acorda Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BLANK BURKHARDStock Award(Grant) at price 0.00 per share.D2020-09-17Officer3.02k
COHEN RONStock Award(Grant) at price 0.00 per share.D2020-09-17Chief Executive Officer8.54k
LAWRENCE DAVID WStock Award(Grant) at price 0.00 per share.D2020-09-17Officer3.02k
SABELLA LAUREN MStock Award(Grant) at price 0.00 per share.D2020-09-17Officer3.02k
COHEN RONSale at price 1.60 per share.D2019-12-02Chief Executive Officer4.7k
WASMAN JANESale at price 1.60 per share.D2019-12-02General Counsel2.23k
LAWRENCE DAVID WSale at price 1.60 per share.D2019-12-02Officer1.18k
SABELLA LAUREN MSale at price 1.60 per share.D2019-12-02Officer1.51k
BLANK BURKHARDStock Award(Grant) at price 0.00 per share.D2019-03-08Officer9.04k
COHEN RONStock Award(Grant) at price 0.00 per share.D2019-03-08Chief Executive Officer25.63k
WASMAN JANEStock Award(Grant) at price 0.00 per share.D2019-03-08General Counsel12.81k
LAWRENCE DAVID WStock Award(Grant) at price 0.00 per share.D2019-03-08Officer9.04k
SABELLA LAUREN MStock Award(Grant) at price 0.00 per share.D2019-03-08Officer9.04k
HINDMAN ANDREW ASAStock Award(Grant) at price 0.00 per share.D2019-03-08Officer9.04k
LAWRENCE DAVID WSale at price 13.18 per share.D2019-02-22Officer761
SABELLA LAUREN MSale at price 13.18 per share.D2019-02-22Officer761
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.01 per share.I2019-01-30Beneficial Owner of more than 10% of a Class of Security7k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.00 - 16.03 per share.I2019-01-25Beneficial Owner of more than 10% of a Class of Security11k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.01 - 16.02 per share.I2019-01-23Beneficial Owner of more than 10% of a Class of Security97.84k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.24 - 16.86 per share.I2019-01-18Beneficial Owner of more than 10% of a Class of Security139.36k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.60 - 16.94 per share.I2019-01-16Beneficial Owner of more than 10% of a Class of Security93.35k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 17.40 per share.I2019-01-11Beneficial Owner of more than 10% of a Class of Security40.39k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 17.05 - 17.29 per share.I2019-01-10Beneficial Owner of more than 10% of a Class of Security162.49k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.24 - 16.56 per share.I2019-01-08Beneficial Owner of more than 10% of a Class of Security134.17k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 15.74 - 16.61 per share.I2019-01-04Beneficial Owner of more than 10% of a Class of Security55.21k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 14.99 per share.I2018-12-28Beneficial Owner of more than 10% of a Class of Security52.89k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 14.66 per share.I2018-12-27Beneficial Owner of more than 10% of a Class of Security100k
BLANK BURKHARDStock Award(Grant) at price 0.00 per share.D2018-12-21Officer2.1k
COHEN RONStock Award(Grant) at price 0.00 per share.D2018-12-21Chief Executive Officer5.98k
WASMAN JANEStock Award(Grant) at price 0.00 per share.D2018-12-21President2.5k
LAWRENCE DAVID WStock Award(Grant) at price 0.00 per share.D2018-12-21Officer2.2k
SABELLA LAUREN MStock Award(Grant) at price 0.00 per share.D2018-12-21Officer2.2k
HINDMAN ANDREW ASAStock Award(Grant) at price 0.00 per share.D2018-12-21Officer2.3k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 13.23 per share.I2018-12-21Beneficial Owner of more than 10% of a Class of Security40.51k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 14.03 - 16.03 per share.I2018-12-20Beneficial Owner of more than 10% of a Class of Security45k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.49 - 16.97 per share.I2018-12-18Beneficial Owner of more than 10% of a Class of Security121.85k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.15 - 16.27 per share.I2018-12-14Beneficial Owner of more than 10% of a Class of Security61.86k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.30 per share.I2018-12-12Beneficial Owner of more than 10% of a Class of Security300k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 18.77 - 19.07 per share.I2018-12-10Beneficial Owner of more than 10% of a Class of Security60.21k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 18.43 - 20.60 per share.I2018-12-06Beneficial Owner of more than 10% of a Class of Security43.8k
COHEN RONSale at price 20.60 per share.D2018-12-03Chief Executive Officer3.62k
WASMAN JANESale at price 20.52 per share.D2018-12-03General Counsel3.07k
LAWRENCE DAVID WSale at price 20.55 per share.D2018-12-03Officer2.49k
SABELLA LAUREN MSale at price 20.20 - 20.66 per share.D2018-12-03Officer5.19k
HINDMAN ANDREW ASASale at price 20.56 per share.D2018-12-03Officer753
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 20.20 - 20.70 per share.I2018-12-03Beneficial Owner of more than 10% of a Class of Security225k
RANDALL LORIN JSale at price 19.98 per share.D2018-11-26Director1.9k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.91 - 17.09 per share.I2018-10-11Beneficial Owner of more than 10% of a Class of Security143.58k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 16.49 - 17.87 per share.I2018-10-09Beneficial Owner of more than 10% of a Class of Security153.86k
SCOPIA CAPITAL MANAGEMENT, L.P.Sale at price 18.89 - 19.48 per share.I2018-10-04Beneficial Owner of more than 10% of a Class of Security126.46k
BLANK BURKHARDStock Award(Grant) at price 0.00 per share.D2018-09-10Officer2.1k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Acorda Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Acorda Therapeutics Inc

Here is the result of two systematic investment strategies applied to Acorda Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Acorda Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Acorda Therapeutics Inc:

Acorda Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -59.26% on the backtest period.

Performance at glance

Performance

-59.26 %

Latent gain

-1055.3 $

Invested capital

1780.86 $

Annualized return

-14.45 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Acorda Therapeutics Inc

This is the result of two momentum investment strategies applied to Acorda Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Acorda Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Acorda Therapeutics Inc:

Acorda Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -40.98% of return on Acorda Therapeutics Inc. That represents -2395.5$ of latent gain with 5844.82$ of employed capital.
  • The second momentum investment strategy would give -51.11% of return on Acorda Therapeutics Inc. That represents -1488.62$ of latent gain with 2912.58$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-40.98 %

Latent gain

-2395.5 $

Invested capital

5844.82 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-51.11 %

Latent gain

-1488.62 $

Invested capital

2912.58 $

Annualized return

-14.12 %

Momentum equity curve on Acorda Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Acorda Therapeutics Inc:

Acorda Therapeutics Inc momentum equity

Note: the dividends potentially given by Acorda Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Acorda Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Acorda Therapeutics Inc since the beginning:

Acorda Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Acorda Therapeutics Inc

Buy the dip entry openings on Acorda Therapeutics Inc

Acorda Therapeutics Inc

The performance achieved by the robo-advisor on Acorda Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Acorda Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Acorda Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Acorda Therapeutics Inc

The following chart shows the result of the investment strategy applied to Acorda Therapeutics Inc:

Acorda Therapeutics Inc

Note: the dividends potentially given by Acorda Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Acorda Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Acorda Therapeutics Inc:

Acorda Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Acorda Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Acorda Therapeutics Inc.

Equity curve comparison on Acorda Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Acorda Therapeutics Inc investment strategy comparison

Employed capital comparison on Acorda Therapeutics Inc

Acorda Therapeutics Inc investment comparison

Performance comparison on Acorda Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -59.26% -1055.3$ 1780.86$ -14.45%
Momentum 1 quarter -40.98% -2395.5$ 5844.82$ -10.62%
Momentum 2 quarters -51.11% -1488.62$ 2912.58$ -14.12%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-14.45 %

Momentum 1Q

-14.12 %

Momentum 2Q

-14.12 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Acorda Therapeutics Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • JOHNSON HLDGS

  • Note: The algorithm computes the probability of correlation between Acorda Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Acorda Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Acorda Therapeutics Inc
    Country United States
    City Ardsley
    Address 420 Saw Mill River Road
    Phone 914 347 4300
    Website www.acorda.com
    FullTime employees 118
    Industry Drug Manufacturers—Specialty & Generic
    Sector Healthcare
    Exchange XNAS
    Ticker ACOR
    Market www.nasdaq.com

    Acorda Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown